Article · 19 Jun 2026
Conference abstract
Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Enhanced cardiovascular risk in Ankylosing Spondylitis (AS) provides a strong rationale for early therapeutical intervention. In view of the proven benefit of statins in atherosclerotic vascular disease, it was aimed to investigate the effect of rosuvastatin on Endothelial Dysfunction (ED) and inflammatory disease activity in AS. Methods: 32 AS patients were randomized to receive 24 weeks of treatment with rosuvastatin (10 mg/day, n=17) and placebo (n=15) as an adjunct to existing stable antirheumatic drugs. Flow mediated dilatation (FMD) was assessed by Angiodefender TM (Everest Genomic Ann Arbor, United States). Inflammatory measures (BASDAI, BASFI, CRP and ESR) and proinflammatory cytokines (TNF-α, IL-6 and IL-1) were measured at baseline and after treatment. Lipids and adhesion molecules (ICAM-1 and VCAM-1) were estimated at baseline and after treatment. Results: At baseline, inflammatory measures, pro inflammatory cytokines and adhesion molecules were elevated among both groups. After treatment with rosuvastatin, FMD improved significantly (p<0.01). Levels of inflammatory measures, TNF-α, IL-6 and ICAM-1 decreased significantly (p<0.01) after treatment with rosuvastatin. Rosuvastatin exerted positive effect on lipid spectrum. No significant change in the placebo group. Significant negative correlation was observed between FMD and IL-6, ICAM-1, CRP after treatment with rosuvastatin. Conclusion: First study to show that rosuvastatin improves inflammatory disease activity and ED in AS. Rosuvastatin lowers the proinflammatory cytokines, especially IL-6 and TNF-α, which downregulates adhesion molecules and CRP production which in turns improves ED. Improvement in endothelial dysfunction in AS occurs through both cholesterol independent and dependent pathways. Rosuvastatin can mediate modest but clinically apparent anti-inflammatory effects with modification of vascular risk factors in the context of high-grade autoimmune inflammation of AS.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmacovigilance.
Article · 19 Jun 2026
Strengthening Healthcare Outcomes Through Effective Drug Safety Practices
Article · 19 Jun 2026
Expanding Patient Care Through Clinical Pharmacy Services in Modern Healthcare
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacovigilance
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Nidhi Garg”

